Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying RC288, a drug being evaluated for its safety, tolerability, and effectiveness in treating locally advanced unresectable or metastatic malignant solid tumors. The study aims to find the highest safe dose and the recommended dose for further testing while assessing how well the drug works at that dose. This is a Phase III clinical trial sponsored by RemeGen Co., Ltd., involving multiple centers. Participants receive RC288 through intravenous infusion. The study includes six predefined dose levels that increase stepwise in Phase I to determine the maximum tolerated or administered dose. In Phase II, the recommended dose is further tested across various cancer types to evaluate safety and effectiveness. Patients continue treatment until they experience unacceptable side effects, disease progression, or meet criteria for withdrawal. During the study, participants undergo regular assessments including imaging to measure tumor responses, evaluations for adverse events, and monitoring of vital organ functions. Researchers will collect data over 24 months on dose-limiting toxicities, side effect severity, and tumor response rates using established criteria. The trial lasts up to approximately four years with ongoing safety monitoring and efficacy assessments throughout.
Actively Recruiting
Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.
Actively Recruiting
Healthy Volunteer
This research aims to develop and evaluate a teaching curriculum for tracheal intubation using CT-based three-dimensional imaging and 3D printing technologies. The goal is to help students learn anatomical knowledge, operational skills, and special handling techniques for both normal and difficult airways. The study compares this new curriculum with traditional teaching methods to assess their relative effectiveness. Participants are divided into two groups. Group A receives training with the newly developed 3D curriculum, while Group B is trained using traditional teaching, which involves instructors explaining the material via PowerPoint, highlighting key points, answering questions, and summarizing the content. Both groups cover the same teaching content. After training, students perform tracheal intubation on patients. During the study, researchers will evaluate the success rate of endotracheal intubation over approximately one year. Additional outcomes include complications related to intubation and student satisfaction and confidence scores. The study monitors the participants performance, satisfaction, and training outcomes to compare the two teaching methods effectively.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a phase III clinical trial to evaluate the protective effects, safety, and immune response of a recombinant respiratory syncytial virus RSV vaccine made with CHO cells. The study involves adults aged 60 years and older, including about 30% aged 70 and above, with a balanced mix of men and women. Participants are randomly assigned to receive either the vaccine or a placebo, and the trial aims to assess the vaccines ability to prevent lower respiratory tract disease caused by RSV. Participants will receive one dose of either the investigational vaccine or a placebo injection on Day 0. The vaccine dose involves mixing an antigen powder with an adjuvant liquid before intramuscular injection into the upper arm. The placebo consists of a sodium chloride solution administered similarly. A subset of 1,200 participants will have their immune response closely studied. The trials evaluation period can last up to 12 months following vaccination. During the study, participants will be monitored for respiratory illnesses, including lower respiratory tract disease and acute respiratory infections, with assessments starting 14 days after vaccination and continuing for up to a year. Safety will be carefully tracked through reports of adverse events within days to a year after vaccination. The study includes scheduled follow-ups to collect data on vaccine effectiveness and immune response. Participation may last up to 12 months from the vaccination date.
Actively Recruiting
Researchers are developing a large, multi-center database platform called the brain-heart comorbidity platform to collect and analyze clinical, sample, and imaging data from patients newly diagnosed with various cardiovascular-related diseases. This observational study aims to integrate artificial intelligence into this platform to enhance research on brain-heart comorbid conditions, supported by the National Key Research and Development Program. The platform stores data on a physical server or virtual appliance at participating institutions, connected through a network that allows for data queries and aggregation across centers. The study collects information on patients diagnosed with diseases identified by specific ICD-10-CM codes, including ischemic heart diseases, cardiac arrest, atrial fibrillation, heart failure, aortic diseases, subarachnoid hemorrhage, intracerebral hemorrhage, cerebral infarction, vascular occlusions, cerebral aneurysm, moyamoya disease, and arteriovenous malformations. Participants undergo multi-disciplinary assessments and their data is carefully checked for quality through a standardized process that removes incomplete or inaccurate records. The main outcomes measured include rates of all-cause mortality and cardiovascular events at discharge and 30 days. This ongoing registry enables continuous data collection and evaluation to better understand outcomes for patients with brain-heart comorbidities.
Actively Recruiting
Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.
Actively Recruiting
Researchers are evaluating the efficacy and safety of SG301 SC Injection in people diagnosed with Systemic Lupus Erythematosus SLE. This multicenter, randomized, double-blind, placebo-controlled Phase 2 study aims to measure how well the treatment works based on the Systemic Lupus Erythematosus Responder Index -4 SRI-4 response rate. Secondary goals include assessing the safety, how the drug is processed in the body, and its immune effects. Participants will receive SG301 SC Injection or a placebo through a series of 16 subcutaneous injections. The dosing schedule starts with one injection per week for 8 weeks, followed by injections every two weeks for another 8 doses. Some participants may receive placebo injections mixed within the treatment regimen. The study is designed with parallel groups and includes careful monitoring of drug effects and immune responses. During the study, participants will be regularly evaluated for disease activity, side effects, and immune responses. The main measure of success is the proportion of participants achieving an improved SRI-4 score from baseline to week 25. Study visits will include clinical assessments and safety monitoring. The total participant involvement extends through the treatment period and follow-up until study completion, expected by the end of 2027.